HLN1 N Stock Overview
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Haleon plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£138.30 |
| 52 Week High | UK£151.22 |
| 52 Week Low | UK£137.00 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | -1.21% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| HLN1 N | MX Personal Products | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how HLN1 N performed against the MX Personal Products industry.
Return vs Market: Insufficient data to determine how HLN1 N performed against the MX Market.
Price Volatility
| HLN1 N volatility | |
|---|---|
| HLN1 N Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: HLN1 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HLN1 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 25,408 | Brian McNamara | www.haleon.com |
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues.
Haleon plc Fundamentals Summary
| HLN1 N fundamental statistics | |
|---|---|
| Market cap | Mex$699.29b |
| Earnings (TTM) | Mex$24.83b |
| Revenue (TTM) | Mex$257.57b |
28.2x
P/E Ratio2.7x
P/S RatioIs HLN1 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLN1 N income statement (TTM) | |
|---|---|
| Revenue | UK£11.24b |
| Cost of Revenue | UK£4.28b |
| Gross Profit | UK£6.96b |
| Other Expenses | UK£5.88b |
| Earnings | UK£1.08b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 61.94% |
| Net Profit Margin | 9.64% |
| Debt/Equity Ratio | 57.4% |
How did HLN1 N perform over the long term?
See historical performance and comparison